Unicycive Therapeutics
Develops kidney-disease candidates for dialysis and acute injury.
$5.32
After-hours close+0.06 (+1.14%)
At close$5.26(−4.36%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.32 | — | — |
| Aug 2026 | −$0.47 | −$0.06 | +87.3% |
| Aug 2026 | −$0.47 | −$0.06 | +87.3% |
| May 2026 | −$0.55 | −$0.54 | +1.8% |
| Mar 2026 | −$0.50 | −$0.32 | +36.6% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| Mar 2025 | |||
| Mar 2025 | |||
| Nov 2024 | −$0.13 | — | — |
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.32 | — | — | $902.8K | — | — |
| Aug 13, 2026 | −$0.47 | −$0.06 | +87.3% | $22.2M | — | — |
| Aug 12, 2026 | −$0.47 | −$0.06 | +87.3% | $22.2M | — | — |
| May 12, 2026 | −$0.55 | −$0.54 | +1.8% | $11.1M | — | — |
| Mar 30, 2026 | −$0.50 | −$0.32 | +36.6% | $517.0K | — | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 14, 2025 | ||||||
| Mar 31, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 12, 2024 | −$0.13 | — | — | — | — | — |
| Aug 14, 2024 | ||||||
| May 13, 2024 | ||||||
| Mar 28, 2024 | ||||||
| Nov 14, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 16, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 15, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Nov 11, 2021 | ||||||
| Aug 16, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||